Please wait while the formulary information is being retrieved.
ANTI-DIARRHEAL (BISMUTH SUBSALICYLATE)
- Diarrhea
- Diarrhea
- Dyspepsia
- Diarrhea secondary to inflammatory bowel disease
- Traveler's diarrhea
- Ultra A-d Tablet
- Stomach Relief Original Oral Suspension
- Stomach Relief Original Oral Susp
- Stomach Relief Oral Suspension
- Soothe Regular Strength Oral Suspension
- Pink Bismuth Oral Suspension
- Pink Bismuth Oral Susp
- Pepto-bismol Oral Suspension
- Loperamide Tablet
- Loperamide Capsule
- Kaopectate (bismuth Subsalicylate) Oral Suspension
- K-pec Antidiarrheal (bism Sub) Oral Suspension
- Imodium A-d Tablet
- Imodium A-d Capsule
- Geri-pectate Oral Suspension
- Digestive Relief Oral Suspension
- Diarrhea Relief (bismuth Subsalicylate) Oral Suspension
- Diamode Tablet
- Bismatrol Oral Suspension
- Anti-diarrheal Oral Suspension
- Anti-diarrheal (loperamide) Tablet
- Anti-diarrheal (loperamide) Capsule
- By Indication
2 mg tablet
- 2 tablets (4 mg) by oral route after 1St loose stool and 1 tablet (2 mg) after each next bowel movement; do not exceed 16 mg in 24Hrs
262 mg/15 mL oral suspension
- Dosage information is not available
Original 262 mg/15 mL oral suspension
- Dosage information is not available
262 mg/15 mL oral suspension
- Dosage information is not available
262 mg/15 mL oral suspension
- Dosage information is not available
525 mg/15 mL oral suspension
- Dosage information is not available
Regular Strength 262 mg/15 mL oral suspension
- Dosage information is not available
262 mg/15 mL oral suspension
- Dosage information is not available
525 mg/15 mL oral suspension
- Dosage information is not available
262 mg/15 mL oral suspension
- Dosage information is not available
525 mg/15 mL oral suspension
- Dosage information is not available
262 mg/15 mL oral suspension
- Dosage information is not available
2 mg tablet
- 2 tablets (4 mg) by oral route after 1St loose stool and 1 tablet (2 mg) after each next bowel movement; do not exceed 16 mg in 24Hrs
2 mg capsule
- 2 capsules (4 mg) by oral route after 1St loose stool, followed by 1 capsule after each subsequent loose stool not to exceed 16 mg/day
(bismuth subsalicylate) 262 mg/15 mL oral suspension
- Dosage information is not available
Antidiarrheal (bism sub) 262 mg/15 mL oral suspension
- Dosage information is not available
2 mg tablet
- 2 tablets (4 mg) by oral route after 1St loose stool and 1 tablet (2 mg) after each next bowel movement; do not exceed 16 mg in 24Hrs
2 mg capsule
- 2 capsules (4 mg) by oral route after 1St loose stool, followed by 1 capsule after each subsequent loose stool not to exceed 16 mg/day
262 mg/15 mL oral suspension
- Dosage information is not available
262 mg/15 mL oral suspension
- Dosage information is not available
(bismuth subsalicylate) 262 mg/15 mL oral suspension
- Dosage information is not available
2 mg tablet
- 2 tablets (4 mg) by oral route after 1St loose stool and 1 tablet (2 mg) after each next bowel movement; do not exceed 16 mg in 24Hrs
262 mg/15 mL oral suspension
- Dosage information is not available
525 mg/15 mL oral suspension
- Dosage information is not available
262 mg/15 mL oral suspension
- Dosage information is not available
(loperamide) 2 mg tablet
- 2 tablets (4 mg) by oral route after 1St loose stool and 1 tablet (2 mg) after each next bowel movement; do not exceed 16 mg in 24Hrs
2 mg tablet
- 2 tablets (4 mg) by oral route after 1St loose stool and 1 tablet (2 mg) after each next bowel movement; do not exceed 16 mg in 24Hrs
(loperamide) 2 mg capsule
- 2 capsules (4 mg) by oral route after 1St loose stool, followed by 1 capsule after each subsequent loose stool not to exceed 16 mg/day
Diarrhea
- 2 tablets (4 mg) by oral route after 1St loose stool and 1 tablet (2 mg) after each next bowel movement; do not exceed 16 mg in 24Hrs
- 2 capsules (4 mg) by oral route after 1St loose stool, followed by 1 capsule after each subsequent loose stool not to exceed 16 mg/day
Diarrhea secondary to inflammatory bowel disease
- 2 capsules (4 mg) by oral route after 1St loose stool, followed by 1 capsule after each subsequent loose stool not to exceed 16 mg/day
- ketorolac
- Sprix
Contraindicated
- Adoxa
- Avidoxy
- Coumadin
- demeclocycline
- Doryx
- doxycycline calcium
- doxycycline hyclate
- doxycycline monohydrate
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- Jantoven
- Methotrexate (anti-rheumatic)
- methotrexate sodium
- methotrexate sodium (PF)
- Minocin
- minocycline
- Monodox
- Morgidox
- Oracea
- Rheumatrex
- Solodyn
- tetracycline
- Trexall
- varicella virus vacc live (PF)
- Varivax (pf)
- Vibramycin
- warfarin
Severe
Moderate
- A-hydrocort
- A-methapred
- acetazolamide
- acetazolamide sodium
- Amaryl
- Anucort-hc
- Anusol-hc
- Aristospan Intra-articular
- Aristospan Intralesional
- Arixtra
- betamethasone acet & sod phos
- budesonide
- Celestone Soluspan
- chloroquine phosphate
- colchicine-probenecid
- Colocort
- Cortef
- Cortenema
- Cortifoam
- cortisone
- dalteparin (porcine)
- Depacon
- Depakene
- Depakote
- Depakote Er
- Depakote Sprinkles
- Depo-medrol
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- dextromethorphan-quinidine
- Diabeta
- Diamox Sequels
- divalproex
- Duetact
- Elmiron
- eltrombopag
- enoxaparin
- Entocort Ec
- Ez Use Joint-tunnel-trigger
- First-duke's
- First-mary's Mouthwash
- Flo-pred
- fludrocortisone
- fondaparinux
- Fragmin
- glimepiride
- glipizide
- glipizide-metformin
- Glucotrol
- Glucotrol Xl
- Glucovance
- glyburide
- glyburide micronized
- glyburide-metformin
- Glynase
- Grx Hicort 25
- Hemril-30
- heparin (porcine)
- heparin (porcine) in D5W
- heparin(porcine) in 0.45% NaCl
- heparin, porcine (PF)
- hydrocortisone
- hydrocortisone acetate
- hydrocortisone sod succ (PF)
- hydrocortisone sod succinate
- hydroxychloroquine
- Invirase
- Kenalog
- Lovenox
- Medrol
- Medrol (pak)
- methazolamide
- methylprednisolone
- methylprednisolone acetate
- methylprednisolone sod suc(PF)
- methylprednisolone sodium succ
- methylprednisolone-bupivacaine
- Millipred
- Millipred Dp
- nateglinide
- Neptazane
- Nuedexta
- nystatin-hydrocortisone-diphen
- nystatin-TCN-HC-diphenhydramin
- Orapred
- Orapred Odt
- Pediapred
- pentosan polysulfate sodium
- Physicians Ez Use M-pred
- pioglitazone-glimepiride
- Plaquenil
- prednisolone
- prednisolone acetate
- prednisolone sodium phosphate
- prednisone
- Prednisone Intensol
- probenecid
- Proctocort
- Promacta
- quinidine gluconate
- quinidine sulfate
- Rayos
- Rectacort-hc
- saquinavir mesylate
- Solu-cortef
- Solu-cortef (pf)
- Solu-medrol
- Solu-medrol (pf)
- Starlix
- Stavzor
- tolazamide
- tolbutamide
- triamcinolone acetonide
- triamcinolone hexacetonide
- triamcinolone-lidocaine
- Uceris
- valproate sodium
- valproic acid
- valproic acid (as sodium salt)
- Veripred 20
- Congenital long QT syndrome
- Lactating mother
- Paralytic ileus
Contraindicated
- Bloody diarrhea
- Diabetes mellitus
- Increased risk of bleeding due to coagulation disorder
- Infectious diarrhea
- Prolonged QT interval
- Torsades de pointes
Severe
Moderate
- Disease of liver
- Gout
- Kidney disease with reduction in GFR
ANTI-DIARRHEAL (BISMUTH SUBSALICYLATE)
- Diarrhea
- Diarrhea
- Dyspepsia
- Diarrhea secondary to inflammatory bowel disease
- Traveler's diarrhea
- None
- Black stools
- Tongue discoloration
More Frequent
Severe
Less Severe
- None
- Constipation
- Dizziness
- Pruritus of skin
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Allergic dermatitis
- Anaphylaxis
- Angioedema
- Erythema multiforme
- Paralytic ileus
- Prolonged QT interval
- Skin rash
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
- Toxic megacolon
- Urinary retention
Less Severe
- Abdominal pain with cramps
- Drowsy
- Dyspepsia
- Flatulence
- Nausea
- Urticaria
- Vomiting
- Xerostomia
Contraindicated
Loperamide
Risk of respiratory depression and serious cardiac adverse reactions. Contraindicated age < 2 years.
- 1 Day – 2 Years
- 1 Risk of respiratory depression and serious cardiac adverse reactions. Contraindicated age < 2 years.
Severe Precaution
Bismuth Subsalicylate
Do not use in current or recovery from varicella or influenza illness.
Risk of CNS effects, somnolence, especially w/dehydration. Use extreme caution. No safety and efficacy established.
- 1 Day – 16 Years
- Do not use in current or recovery from varicella or influenza illness.
- 2 Years – 13 Years
- Do not use in current or recovery from varicella or influenza illness.
Loperamide
Do not use in current or recovery from varicella or influenza illness.
Risk of CNS effects, somnolence, especially w/dehydration. Use extreme caution. No safety and efficacy established.
- 1 Day – 16 Years
- Risk of CNS effects, somnolence, especially w/dehydration. Use extreme caution. No safety and efficacy established.
- 2 Years – 13 Years
- Risk of CNS effects, somnolence, especially w/dehydration. Use extreme caution. No safety and efficacy established.
Management or Monitoring Precaution
None
Bismuth
- Severity Level:
2
- Additional Notes: Do not use for long periods or in high doses
Loperamide Hydrochloride
- Severity Level:
B
- Additional Notes:
Contraindicated
Bismuth
One report of metabol acidosis w/asa;Risk of reye's syn w/viral illness/fever
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | One report of metabol acidosis w/asa;Risk of reye's syn w/viral illness/fever |
Precaution Exists
Loperamide Hcl
Insufficient data available; limited suggest low levels excreted
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; limited suggest low levels excreted |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Bismuth
Increased risk of fecal impaction. Sensitivity to toxic effects more likely.
General-Use not recommended for the following diarrhea diagnosis: severe infectious gastroenteritis, unknown cause. Cardiovascular-Avoid higher than recommended doses in elderly due to higher risk for Torsades de Pointes at these higher doses.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
Loperamide Hydrochloride
Increased risk of fecal impaction. Sensitivity to toxic effects more likely.
General-Use not recommended for the following diarrhea diagnosis: severe infectious gastroenteritis, unknown cause. Cardiovascular-Avoid higher than recommended doses in elderly due to higher risk for Torsades de Pointes at these higher doses.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: N HEDIS: N STOPP: Y
No Known Risk
None
- None
| Diarrhea | |
| K59.1 | Functional diarrhea |
| P78.3 | Noninfective neonatal diarrhea |
| R19.7 | Diarrhea, unspecified |
| Diarrhea secondary to inflammatory bowel disease | |
| R19.7 | Diarrhea, unspecified |
| Dyspepsia | |
| K30 | Functional dyspepsia |
| Traveler's diarrhea | |
| A02.0 | Salmonella enteritis |
| A03 | Shigellosis |
| A03.0 | Shigellosis due to shigella dysenteriae |
| A03.1 | Shigellosis due to shigella flexneri |
| A03.2 | Shigellosis due to shigella boydii |
| A03.3 | Shigellosis due to shigella sonnei |
| A03.8 | Other shigellosis |
| A03.9 | Shigellosis, unspecified |
| A04.0 | Enteropathogenic escherichia coli infection |
| A04.1 | Enterotoxigenic escherichia coli infection |
| A04.2 | Enteroinvasive escherichia coli infection |
| A04.3 | Enterohemorrhagic escherichia coli infection |
| A04.4 | Other intestinal escherichia coli infections |
| A04.5 | Campylobacter enteritis |
| A09 | Infectious gastroenteritis and colitis, unspecified |
| 0-9 | A-Z |
|---|---|
| A02.0 | Salmonella enteritis |
| A03 | Shigellosis |
| A03.0 | Shigellosis due to shigella dysenteriae |
| A03.1 | Shigellosis due to shigella flexneri |
| A03.2 | Shigellosis due to shigella boydii |
| A03.3 | Shigellosis due to shigella sonnei |
| A03.8 | Other shigellosis |
| A03.9 | Shigellosis, unspecified |
| A04.0 | Enteropathogenic escherichia coli infection |
| A04.1 | Enterotoxigenic escherichia coli infection |
| A04.2 | Enteroinvasive escherichia coli infection |
| A04.3 | Enterohemorrhagic escherichia coli infection |
| A04.4 | Other intestinal escherichia coli infections |
| A04.5 | Campylobacter enteritis |
| A09 | Infectious gastroenteritis and colitis, unspecified |
| K30 | Functional dyspepsia |
| K59.1 | Functional diarrhea |
| P78.3 | Noninfective neonatal diarrhea |
| R19.7 | Diarrhea, unspecified |
| R19.7 | Diarrhea, unspecified |
Formulary Reference Tool